Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Rendell

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Diabetes Care|April 24, 2014
Artifactual hypoglycemia: an old term for a new classificationValentina D Tarasova, Mohsen Zena, Marc Rendell
Expert Opinion on Drug Safety|February 12, 2013
Glargine safety, diabetes and cancerMarc Rendell, Halis Kaan Akturk, Sri Harsha Tella
Expert Opinion on Pharmacotherapy|March 17, 2009
Insulin Glargine: a review 8 years after its introductionStanislav Goykhman, Andjela Drincic, Jean Claude Desmangles, et al.
The American Journal of Bioethics : AJOB|June 15, 2012
Ethical dilemma of mandated contraception in pharmaceutical research at catholic medical institutionsMurray Joseph Casey, Richard O'Brien, Marc Rendell, et al.
JAMA|September 26, 2013
Controversy over contraception coverage--replyMarc Rendell, Josef V M Welie, Eric A Zimmer
Current Medical Research and Opinion|February 5, 2003
Cilostazol treatment of claudication in diabetic patientsMarc Rendell, Alan T Cariski, Norbert Hittel, et al.
Expert Review of Endocrinology & Metabolism|February 10, 2019
The future of inpatient diabetes management: glucose as the sixth vital signMarc Rendell, Saraswathi Saiprasad, Alejandro G Trepp-Carrasco, et al.
Journal of the American Academy of Dermatology|May 3, 2011
Skin blood flow abnormalities in diabetic dermopathyAlexandra Brugler, Shaun Thompson, Scott Turner, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|August 28, 2010
Skin blood flow in patients with stage 5 chronic kidney disease on hemodialysisBinh Ngo, Christine Rongey, Bryan Hiscox, et al.
Drugs|June 12, 2013
A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugsVenkata M Alla, Vrinda Agrawal, Andrew DeNazareth, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Diabetes Care|April 24, 2014
Artifactual hypoglycemia: an old term for a new classificationValentina D Tarasova, Mohsen Zena, Marc Rendell
Expert Opinion on Drug Safety|February 12, 2013
Glargine safety, diabetes and cancerMarc Rendell, Halis Kaan Akturk, Sri Harsha Tella
Expert Opinion on Pharmacotherapy|March 17, 2009
Insulin Glargine: a review 8 years after its introductionStanislav Goykhman, Andjela Drincic, Jean Claude Desmangles, et al.
The American Journal of Bioethics : AJOB|June 15, 2012
Ethical dilemma of mandated contraception in pharmaceutical research at catholic medical institutionsMurray Joseph Casey, Richard O'Brien, Marc Rendell, et al.
JAMA|September 26, 2013
Controversy over contraception coverage--replyMarc Rendell, Josef V M Welie, Eric A Zimmer
Current Medical Research and Opinion|February 5, 2003
Cilostazol treatment of claudication in diabetic patientsMarc Rendell, Alan T Cariski, Norbert Hittel, et al.
Expert Review of Endocrinology & Metabolism|February 10, 2019
The future of inpatient diabetes management: glucose as the sixth vital signMarc Rendell, Saraswathi Saiprasad, Alejandro G Trepp-Carrasco, et al.
Journal of the American Academy of Dermatology|May 3, 2011
Skin blood flow abnormalities in diabetic dermopathyAlexandra Brugler, Shaun Thompson, Scott Turner, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|August 28, 2010
Skin blood flow in patients with stage 5 chronic kidney disease on hemodialysisBinh Ngo, Christine Rongey, Bryan Hiscox, et al.
Drugs|June 12, 2013
A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugsVenkata M Alla, Vrinda Agrawal, Andrew DeNazareth, et al.
Pageof 5